T Cell

T-cells are a critical component of the adaptive immune system and are indispensable in protecting humans from pathogenic infections.

Adoptive T Cell Therapy Methodology

Adoptive T cell therapy is a type of immunotherapy that has the ability to target cancer cells through inherent mechanisms of the immune system.

Adoptive T Cell Therapy Applications

T-Cell Metabolism, Immunodeficiency and Human Disease

CAR-T Cell Toxicity and Safety Profiles

Breakthrough in antigen recognition: TRACeR-I enhances immune targeting

Researchers describe TRACeR-I, a protein platform that can be used to engineer immune responses.

19 Dec 2024

Kaempferol boosts immune tolerance and fights allergies

Kaempferol's role in Treg development is linked to Aldh1a2 activation in dendritic cells, highlighting its potential in suppressing inflammation and allergies.

19 Dec 2024

WashU Medicine receives $10.8 million grant to advance blood cancer research

Continuing its role as a leader in leukemia research, Washington University School of Medicine in St. Louis has been awarded a five-year, $10.8 million grant to further its exceptional programs in leukemia and other blood cancers.

16 Dec 2024

Flavonoid kaempferol could offer natural relief for food allergies

Allergic diseases such as asthma, atopic dermatitis, and food allergies have been increasing in frequency over the last few years.

16 Dec 2024

Multi-omic profiling sheds light on chemo-immunotherapy resistance in lung cancer

The study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and potential therapeutic strategies.

13 Dec 2024

New insights into accelerated aging in young sickle cell patients

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 21 on November 14, 2024, entitled, "Adolescents and young adults with sickle cell disease exhibit accelerated aging with elevated T-cell p16INK4a expression."

11 Dec 2024

TCR sequencing sheds light on tumor immune interactions in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.

11 Dec 2024

New $1.4M grant supports innovative kidney cancer treatment strategy

Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.

10 Dec 2024

First-in-class monoclonal antibody shows promise for rare, aggressive hyperinflammatory condition

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.

9 Dec 2024

EZH2 inhibitors enhance effectiveness of cancer immunotherapies

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma researchers.

5 Dec 2024

PAGER technology unlocks new potential for controlling cellular activity

A basic function of cells is that they act in response to their environments. It makes sense, then, that a goal of scientists is to control that process, making cells respond how they want to what they want.

5 Dec 2024

Cancer cells block T-cell activation, but new therapies restore immune defenses

Cancer cells impair monocyte-mediated T-cell activation by disrupting inflammatory pathways in the tumor microenvironment. Restoring balance through PGE2 inhibition and IFN-I enhancement could renew immune defenses and improve immunotherapy outcomes.

4 Dec 2024

Ultrasound-controlled CRISPR offers precision in treating genetic disorders

Thanks to CRISPR, our medical specialists will soon have unprecedented control over how they treat and prevent some of our most challenging genetic disorders and diseases.

4 Dec 2024

Exploring the potential of MSCs in cancer therapy

A new review was published in Oncotarget's Volume 15 on November 22, 2024, entitled "Mesenchymal stem cells – the secret agents of cancer immunotherapy: Promises, challenges, and surprising twists."

4 Dec 2024

Study cracks the cold case of immunotherapy resistance

A study from the University of Michigan Health Rogel Cancer Center may have, at last, cracked the cold case of immunotherapy resistance.

3 Dec 2024

New immune therapy improves survival and reduces tumor burden in glioblastoma

The Wistar Institute's David B. Weiner, Ph.D. -; Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Smith Charitable Trust Distinguished Professor in Cancer Research -; and his lab have successfully tested a new immune therapy that, in preclinical lab testing, reliably improves survival and reduces tumor burden in glioblastoma.

3 Dec 2024

How carrageenan affects insulin resistance

A randomized controlled trial found that carrageenan, a common food additive, may cause subclinical inflammation and insulin resistance in overweight individuals, mediated by gut permeability and inflammation. Effects were linked to BMI but not observed in non-overweight participants during short-term exposure.

3 Dec 2024